ANI Pharmaceuticals (ANIP) Upgraded by BidaskClub to Buy

BidaskClub upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a buy rating in a report published on Friday, January 5th.

Other research analysts also recently issued research reports about the stock. TheStreet raised shares of ANI Pharmaceuticals from a c+ rating to a b rating in a research report on Thursday, November 16th. Zacks Investment Research raised shares of ANI Pharmaceuticals from a hold rating to a buy rating and set a $71.00 price objective for the company in a research report on Tuesday, November 7th. ValuEngine raised shares of ANI Pharmaceuticals from a hold rating to a buy rating in a report on Saturday, November 4th. Finally, Canaccord Genuity reaffirmed a buy rating on shares of ANI Pharmaceuticals in a report on Thursday, November 2nd. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. ANI Pharmaceuticals currently has an average rating of Buy and a consensus price target of $71.00.

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) traded up $1.24 during mid-day trading on Friday, reaching $72.30. 95,100 shares of the company’s stock traded hands, compared to its average volume of 119,833. ANI Pharmaceuticals has a 12-month low of $42.23 and a 12-month high of $74.70. The firm has a market cap of $841.79, a price-to-earnings ratio of 114.76 and a beta of 2.90. The company has a quick ratio of 2.39, a current ratio of 3.45 and a debt-to-equity ratio of 0.83.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.12. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The company had revenue of $48.16 million during the quarter, compared to the consensus estimate of $48.12 million. During the same quarter last year, the firm posted $1.09 EPS. The company’s quarterly revenue was up 25.0% on a year-over-year basis. equities analysts expect that ANI Pharmaceuticals will post 3.59 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in ANIP. Dimensional Fund Advisors LP boosted its holdings in ANI Pharmaceuticals by 91.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 339,268 shares of the specialty pharmaceutical company’s stock valued at $15,878,000 after purchasing an additional 161,743 shares during the period. JPMorgan Chase & Co. raised its position in shares of ANI Pharmaceuticals by 868.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 104,829 shares of the specialty pharmaceutical company’s stock valued at $5,404,000 after buying an additional 94,002 shares in the last quarter. Vanguard Group Inc. raised its position in shares of ANI Pharmaceuticals by 8.1% in the 2nd quarter. Vanguard Group Inc. now owns 476,948 shares of the specialty pharmaceutical company’s stock valued at $22,322,000 after buying an additional 35,722 shares in the last quarter. Cadence Capital Management LLC raised its position in shares of ANI Pharmaceuticals by 422.2% in the 3rd quarter. Cadence Capital Management LLC now owns 33,402 shares of the specialty pharmaceutical company’s stock valued at $1,753,000 after buying an additional 27,005 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ raised its position in shares of ANI Pharmaceuticals by 85.5% in the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 54,900 shares of the specialty pharmaceutical company’s stock valued at $2,882,000 after buying an additional 25,300 shares in the last quarter. 55.05% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “ANI Pharmaceuticals (ANIP) Upgraded by BidaskClub to Buy” was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://baseballnewssource.com/markets/ani-pharmaceuticals-anip-lifted-to-buy-at-bidaskclub/1818199.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.